MIM
DNLI icon

Monashee Investment Management’s Denali Therapeutics DNLI Stock Holding History

Monashee Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-91,620
Closed -$1.51M – 47
2025
Q4 		$1.51M Buy
+91,620
New +$1.55M 0.85% 33

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Monashee Investment Management's DNLI Position: Q1 2026 in Review

Monashee Investment Management sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 91,620 shares — an estimated $1.51M sold.

Monashee Investment Management first reported a position in DNLI in Q4 2025 and held it in 1 quarter. The position peaked at $1.51M in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Monashee Investment Management reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Monashee Investment Management sold 91,620 Denali Therapeutics shares in Q1 2026, an estimated $1.51M.
  • Monashee Investment Management first reported a position in Denali Therapeutics in Q4 2025 and held it in 1 quarter.
  • Monashee Investment Management's Denali Therapeutics position peaked at $1.51M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.